Nivolumab in the treatment of malignant melanoma: review of the literature

Nivolumab was developed as a monoclonal antibody against programmed death receptor-1, an immune checkpoint inhibitor which negatively regulates T-cell proliferation and activation. Intravenous administration of nivolumab was approved for the treatment of unresectable malignant melanoma in 2014 in Ja...

Descripción completa

Detalles Bibliográficos
Autores principales: Mashima, Emi, Inoue, Akiha, Sakuragi, Yumiko, Yamaguchi, Takashi, Sasaki, Natsuko, Hara, Yoko, Omoto, Daisuke, Ohmori, Shun, Haruyama, Sanehito, Sawada, Yu, Yoshioka, Manabu, Nishio, Daisuke, Nakamura, Motonobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532168/
https://www.ncbi.nlm.nih.gov/pubmed/26273207
http://dx.doi.org/10.2147/OTT.S62102

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532168/
https://www.ncbi.nlm.nih.gov/pubmed/26273207
http://dx.doi.org/10.2147/OTT.S62102

Ejemplares similares